Structure

InChI Key HYFHYPWGAURHIV-JFIAXGOJSA-N
Smile COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
InChI
InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C29H39NO9
Molecular Weight 545.63
AlogP 2.58
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 9.0
Polar Surface Area 123.99
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 39.0

Pharmacology

Action Mechanism of Action Reference
None Protein synthesis inhibitor FDA Expert PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 D015464 ClinicalTrials
Myelodysplastic Syndromes 1 D009190 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
20.78
Gastrointestinal disorders
13.59
Investigations
11.82
Injury, poisoning and procedural complications
8.92
Skin and subcutaneous tissue disorders
8.37
Nervous system disorders
5.46
Blood and lymphatic system disorders
4.79
Vascular disorders
4.75
Respiratory, thoracic and mediastinal disorders
3.38
Metabolism and nutrition disorders
2.83
Musculoskeletal and connective tissue disorders
2.83
Infections and infestations
2.79
Cardiac disorders
2.44

Cross References

Resources Reference
CAS NUMBER 26833-87-4
ChEBI 71019
ChEMBL CHEMBL46286
DrugBank DB04865
DrugCentral 4677
FDA SRS 6FG8041S5B
Guide to Pharmacology 7454
PDB HMT
PubChem 285033
SureChEMBL SCHEMBL12745687
ZINC ZINC000026011099